Cheryl R. Blanchard - Mar 11, 2024 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
President, CEO, Director, Director
Signature
/s/ Cheryl R. Blanchard
Stock symbol
ANIK
Transactions as of
Mar 11, 2024
Transactions value $
-$716,629
Form type
4
Date filed
3/12/2024, 08:04 PM
Previous filing
Mar 5, 2024
Next filing
Mar 19, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +14.4K +12.52% $0.00 130K Mar 11, 2024 Direct F1, F2
transaction ANIK Common Stock Tax liability -$177K -6.97K -5.38% $25.42 123K Mar 11, 2024 Direct F3, F4
transaction ANIK Common Stock Options Exercise $0 +20K +16.31% $0.00 143K Mar 11, 2024 Direct F5
transaction ANIK Common Stock Tax liability -$165K -6.47K -4.54% $25.42 136K Mar 11, 2024 Direct F4, F6
transaction ANIK Common Stock Options Exercise $0 +30.1K +22.07% $0.00 166K Mar 11, 2024 Direct F7
transaction ANIK Common Stock Tax liability -$375K -14.5K -8.74% $25.79 152K Mar 11, 2024 Direct F8, F9
holding ANIK Common Stock 11.7K Mar 11, 2024 Revocable Trust F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise $0 -14.4K -100% $0.00* 0 Mar 11, 2024 Common Stock 14.4K $0.00 Direct F11
transaction ANIK Restricted Stock Unit Options Exercise $0 -20K -33.33% $0.00 40K Mar 11, 2024 Common Stock 20K $0.00 Direct F12
transaction ANIK Restricted Stock Unit Options Exercise $0 -30.1K -50% $0.00 30.1K Mar 11, 2024 Common Stock 30.1K $0.00 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021.
F2 Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 152 shares purchased on May 12, 2023 and 787 shares purchased on November 14, 2023.
F3 Reflects an aggregate of 6,973 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024.
F4 Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations.
F5 Reflects the first vesting installment of RSUs granted on March 9, 2023.
F6 Reflects an aggregate of 6,473 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024.
F7 Reflects the second vesting installment of RSUs granted on March 11, 2022.
F8 Reflects an aggregate of 14,534 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2024.
F9 Reflects the closing price of ANIK common stock on March 11, 2024, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
F10 Consists of shares transferred by Dr. Blanchard to The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which Dr. Blanchard is a beneficiary and the sole trustee.
F11 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022.
F12 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024.
F13 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023.